Aperta Biosciences
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1108 Lavaca St Ste 110-329, Austin, Texa...Phone Number
(512) 270-3960Website
www.apertabio.comRevenue
<$5 MillionIndustry
About Aperta Biosciences
Aperta Biosciences is an emerging biopharma company dedicated to developing novel therapeutics for Ocular Surface Disease (OSD), particularly focusing on conditions such as blepharitis, ocular rosacea, meibomian gland dysfunction, and dry eye disease. The company aims to address not only the symptoms but also the underlying causes of blepharitis, with its lead program APT-001 targeting ocular demodicosis. Founded by a team with extensive experience in ophthalmic indications, Aperta is committed to advancing innovative treatment options for the millions affected by these conditions. Their approach emphasizes a new mechanism of action to effectively eradicate the root causes of blepharitis.Explore more
SIC Code 28,283NAICS Code 32,325Show moreAperta Biosciences Org Chart
Compare Similar Companies to Aperta Biosciences
Compare insights from companies similar to Aperta Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aperta Biosciences Tech Stack
A closer look at the technologies used by Aperta Biosciences
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aperta Biosciences
Sign Up For FreeTo access detailed company insights
Aperta Biosciences is an emerging biopharma company dedicated to developing novel therapeutics for Ocular Surface Disease (OSD), particularly focusing on conditions such as blepharitis, ocular rosacea, meibomian gland dysfunction, and dry eye disease. The company aims to address not only the symptoms but also the underlying causes of blepharitis, w... Read More